Erschienen in:
09.01.2021 | Breast Oncology
Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance ≤ 1 cm: A Matched Cohort Study
verfasst von:
Zhen-Yu Wu, MD, PhD, Hee Jeong Kim, MD, PhD, Jongwon Lee, MD, PhD, Il Yong Chung, MD, Jisun Kim, MD, PhD, Sae-Byul Lee, MD, PhD, Byung-Ho Son, MD, PhD, Jing Han, MD, Hyun Ho Han, MD, PhD, Jin-Sup Eom, MD, PhD, Sung-Bae Kim, MD, PhD, Kyung Hae Jung, MD, PhD, Gyungyub Gong, MD, PhD, Hak Hee Kim, MD, PhD, Sei-Hyun Ahn, MD, PhD, BeomSeok Ko, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Abstract
Background
A short tumor-to-nipple distance (TND) is reported as a strong predictor of nipple-areola complex (NAC) involvement. Eligibility for nipple-sparing mastectomy (NSM) remains controversial, especially regarding TND. In this study, we compared long-term oncologic outcomes after NSM between patients with a TND ≤ 1 cm and those with a TND > 1 cm.
Methods
Overall, 1369 patients with primary breast cancer who underwent NSM with immediate reconstruction from March 2003 to December 2015 were included for analysis. After propensity score matching, 495 patients with a TND ≤ 1 cm (group A) and 495 patients with a TND > 1 cm (group B) on imaging were selected to compare long-term oncologic outcomes.
Results
After matching, the median follow-up periods for surviving patients were 109 months and 112 months for groups A and B, respectively. There were no significant differences between groups with respect to the 5-year cumulative local recurrence (8.1% vs. 6.3%; p = 0.268), NAC recurrence (5.1% vs. 2.8%; p = 0.072), regional recurrence (2.0% vs. 3.6%; p = 0.125), or distant recurrence (5.9% vs. 4.8%; p = 0.480) rates. Furthermore, no significant differences were observed between the groups with respect to the 10-year local recurrence-free survival (87.1% vs. 90.7%; p = 0.164) or disease-free survival (77.9% vs. 81.6%; p = 0.222) rates.
Conclusions
A preoperative TND ≤ 1 cm on imaging should not be contraindicated to NSM as long as there is no involvement of NAC clinically or on imaging and if retroareolar margins are confirmed to be negative for tumor cells.